Compare Stocks: SLN, IONS, CRSP, and RLAY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$42.24 -0.9%	$52.09	$41.75 ▼ $63.45	$4.13B	1.92	1.60 million shs	1.87 million shs
IONS Ionis Pharmaceuticals	$29.06 +6.4%	$43.65	$27.25 ▼ $86.74	$4.55B	0.43	4.39 million shs	5.95 million shs
RLAY Relay Therapeutics	$18.09 +0.1%	$18.37	$6.17 ▼ $21.27	$3.99B	1.74	2.61 million shs	1.48 million shs
SLN Silence Therapeutics	$19.83 +0.2%	$14.66	$4.19 ▼ $19.86	$1.23B	1.34	5.72 million shs	586,512 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	-15.64%	-18.01%	-21.12%	-19.06%
IONS Ionis Pharmaceuticals	0.00%	-26.28%	-34.13%	-49.23%	-60.01%
RLAY Relay Therapeutics	0.00%	-2.74%	+4.57%	-8.91%	+193.19%
SLN Silence Therapeutics	0.00%	+0.51%	+112.09%	+44.53%	+194.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$42.24 -0.9%	$52.09	$41.75 ▼ $63.45	$4.13B	1.92	1.60 million shs	1.87 million shs
IONS Ionis Pharmaceuticals	$29.06 +6.4%	$43.65	$27.25 ▼ $86.74	$4.55B	0.43	4.39 million shs	5.95 million shs
RLAY Relay Therapeutics	$18.09 +0.1%	$18.37	$6.17 ▼ $21.27	$3.99B	1.74	2.61 million shs	1.48 million shs
SLN Silence Therapeutics	$19.83 +0.2%	$14.66	$4.19 ▼ $19.86	$1.23B	1.34	5.72 million shs	586,512 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	-15.64%	-18.01%	-21.12%	-19.06%
IONS Ionis Pharmaceuticals	0.00%	-26.28%	-34.13%	-49.23%	-60.01%
RLAY Relay Therapeutics	0.00%	-2.74%	+4.57%	-8.91%	+193.19%
SLN Silence Therapeutics	0.00%	+0.51%	+112.09%	+44.53%	+194.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.65	Moderate Buy	$72.93	72.65% Upside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$75.71	160.54% Upside
RLAY Relay Therapeutics	2.86	Moderate Buy	$27.00	49.25% Upside
SLN Silence Therapeutics	2.14	Hold	$24.00	21.03% Upside

Current Analyst Ratings Breakdown

Latest SLN, IONS, CRSP, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/10/2026	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$110.00
11/10/2026	IONS Ionis Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$84.00 ➝ $53.00
11/10/2026	IONS Ionis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$85.00 ➝ $60.00
11/10/2026	IONS Ionis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$95.00 ➝ $80.00
11/10/2026	IONS Ionis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$63.00
11/10/2026	IONS Ionis Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$58.00 ➝ $41.00
11/10/2026	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$104.00 ➝ $75.00
11/10/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$85.00 ➝ $70.00
11/10/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$100.00 ➝ $70.00
11/9/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$54.00
11/9/2026	IONS Ionis Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$86.00 ➝ $54.00

(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$3.51M	1,167.32	N/A	N/A	$16.99 per share	2.49
IONS Ionis Pharmaceuticals	$944M	5.13	N/A	N/A	$2.36 per share	12.31
RLAY Relay Therapeutics	$15.35M	260.40	N/A	N/A	$3.71 per share	4.88
SLN Silence Therapeutics	$560K	2,200.78	N/A	N/A	$1.32 per share	15.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$581.60M	-$4.74	N/A	N/A	N/A	-1,812.07%	-25.59%	-17.89%	N/A
IONS Ionis Pharmaceuticals	-$381.39M	-$3.32	N/A	N/A	N/A	-56.98%	-120.62%	-16.99%	N/A
RLAY Relay Therapeutics	-$276.48M	-$1.51	N/A	N/A	N/A	N/A	-40.25%	-36.82%	N/A
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-102.72%	-43.70%	N/A

Latest SLN, IONS, CRSP, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	SLN Silence Therapeutics	-$0.1129	-$0.24	-$0.1271	-$0.24	$0.11 million	N/A
11/9/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.23	-$0.66	+$0.57	-$0.4030	$178.17 million	$242.72 million
11/4/2026	Q3 2026	RLAY Relay Therapeutics	-$0.3968	-$0.37	+$0.0268	-$0.37	$1.62 million	N/A
11/2/2026	Q3 2026	CRSP CRISPR Therapeutics	-$1.06	-$1.15	-$0.09	-$1.15	$14.75 million	$12.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	0.36	16.21	16.21
IONS Ionis Pharmaceuticals	3.42	5.43	7.73
RLAY Relay Therapeutics	N/A	14.62	14.62
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
IONS Ionis Pharmaceuticals	93.86%
RLAY Relay Therapeutics	96.98%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	5.20%
IONS Ionis Pharmaceuticals	1.81%
RLAY Relay Therapeutics	5.04%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	393	97.00 million	91.96 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.54 million	163.53 million	Optionable
RLAY Relay Therapeutics	218	220.96 million	209.82 million	Optionable
SLN Silence Therapeutics	88	62.15 million	60.29 million	Optionable

SLN, IONS, CRSP, and RLAY Headlines

Recent News About These Companies

Silence Therapeutics (NASDAQ:SLN) Reaches New 52-Week High - Here's Why

November 13 at 2:39 PM | marketbeat.com

Silence Therapeutics plc: Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results

November 12 at 9:14 AM | finanznachrichten.de

Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026

November 4, 2026 | aol.comA

Silence Therapeutics (SLN) Set to Post Earnings on Thursday

October 29, 2026 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year High - Still a Buy?

October 26, 2026 | marketbeat.com

Silence Therapeutics (NASDAQ:SLN) Downgraded by Chardan Capital to "Hold"

October 22, 2026 | marketbeat.com

Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN

October 21, 2026 | businesswire.com

Silence Therapeutics' (SLN) Neutral Rating Reaffirmed at HC Wainwright

October 21, 2026 | marketbeat.com

Silence Therapeutics stock closed at $19.58, up 125.58% on a $20 cash bid: bull $113.69, bear $18.52. Is the jump already a completed move to $20, or a print that can reverse ...

October 20, 2026 | financefeeds.comF

Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?

October 20, 2026 | zacks.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)

October 20, 2026 | globenewswire.com

Silence Therapeutics PLC Sponsored ADR (SLN) - What Are Brokerages Thinking About This Stock?

October 20, 2026 | marketbeat.com

Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%

October 19, 2026 | insidermonkey.com

Silence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares Surge

October 19, 2026 | finance.yahoo.com

Silence Therapeutics Soars 125% on All-Cash $1.3 Billion Merck KGaA Buyout: “Immediate and Certain”

October 19, 2026 | finance.yahoo.com

Silence Therapeutics Stock Soars 126% On Merck KGaA Acquisition Deal

October 19, 2026 | rttnews.com

Silence Therapeutics jumps 59% on Merck takeover

October 19, 2026 | proactiveinvestors.com

Traders Buy Large Volume of Silence Therapeutics Call Options (NASDAQ:SLN)

October 19, 2026 | marketbeat.com

SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders

October 19, 2026 | businesswire.com

Silence Therapeutics (NASDAQ:SLN) Hits New 1-Year High - Should You Buy?

October 19, 2026 | marketbeat.com

Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

October 19, 2026 | wsj.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SLN, IONS, CRSP, and RLAY Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$42.24 -0.38 (-0.89%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$42.33 +0.09 (+0.20%)

As of 11/13/2026 07:58 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Ionis Pharmaceuticals NASDAQ:IONS

$29.06 +1.75 (+6.41%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$28.92 -0.14 (-0.48%)

As of 11/13/2026 07:45 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Relay Therapeutics NASDAQ:RLAY

$18.09 +0.01 (+0.06%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$17.80 -0.29 (-1.60%)

As of 11/13/2026 07:30 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$19.83 +0.03 (+0.15%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$19.84 +0.01 (+0.03%)

As of 11/13/2026 07:30 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLN, IONS, CRSP, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLN, IONS, CRSP, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLN, IONS, CRSP, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLN, IONS, CRSP, and RLAY Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Ionis Pharmaceuticals NASDAQ:IONS

Relay Therapeutics NASDAQ:RLAY

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLN, IONS, CRSP, and RLAY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLN, IONS, CRSP, and RLAY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLN, IONS, CRSP, and RLAY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SLN, IONS, CRSP, and RLAY Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Ionis Pharmaceuticals NASDAQ:IONS

Relay Therapeutics NASDAQ:RLAY

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools